During Thursday’s Current trade, Shares of ON Semiconductor Corp(NASDAQ:ON), lost -4.53% to $8.95.
ON Semiconductor ( ON), driving energy efficiency innovations, has introduced a reference design implementing the new Qualcomm® Quick Charge™ 3.0 protocol. The new protocol provides noteworthy efficiency improvements over the existing Quick Charge 2.0 solution. The high efficiency, small form factor reference design supports the Quick Charge 3.0 High Voltage Dedicated Charging Port (HVDCP) Class A and Class B specifications, Qualcomm’s next generation of fast charging technology for smartphones and tablets, in addition to offering backward compatibility to the older Quick Charge 2.0 protocol. Qualcomm Quick Charge 3.0 technology is a product of Qualcomm Technologies, Inc., a partner of Qualcomm Incorporated. The availability of a complete reference design from ON Semiconductor in addition to certified conformance from UL aids the rapid development of small form factor chargers for portable applications with industry leading efficiency.
The reference design highlights the new NCP4371 secondary side charge controller, which allows the charger USB-bus voltage to be changed based on requests from the phone or portable device. To optimize the battery charging time, the USB-bus voltage can be controlled in discrete steps from 3.6V up to 20V. The new charge controller is also suited for use in A4WP wireless charging applications where the voltage can be optimized based on the transmit (TX) portion of the reference design.
ON Semiconductor Corporation manufactures and sells semiconductor components for various electronic devices worldwide. It operates in four segments: Application Products Group, Image Sensor Group, Standard Products Group, and System Solutions Group.
Shares of CTI BioPharma Corp (NASDAQ:CTIC), inclined 2.41% to $1.61, during its current trading session.
CTI BioPharma Corp. ( CTIC) declared that administration will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29 at 8:00 a.m. PDT/11:00 a.m. EDT/5:00 p.m. CEST in New York.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union.
Allergan PLC (NYSE:AGN), during its Thursday’s current trading session decreased -1.70% to $281.75.
Allergan plc (AGN) and Gedeon Richter Plc. declared that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.
Bipolar I disorder and schizophrenia are chronic and disabling mental health disorders. Bipolar I disorder, also known as manic-depressive illness, is a disorder of the brain that is characterized by fluctuations in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Schizophrenia is characterized by delusions, hallucinations, disorganized speech and behavior, and other symptoms that cause social or occupational dysfunction.
The FDA approval of VRAYLAR is based on the results of three 3-week controlled trials in adults with manic or mixed episodes of bipolar I disorder and three 6-week placebo-controlled trials in adults with schizophrenia. In these clinical trials involving more than 2,700 adults, VRAYLAR demonstrated improvement contrast to placebo as measured by Young Mania Rating Scale (YMRS) total scores in patients with bipolar mania and by Positive and Negative Syndrome Scale (PANSS) total scores in patients with schizophrenia. VRAYLAR also demonstrated efficacy as measured by the Clinical Global Impressions-Severity (CGI-S) rating scale, the secondary efficacy endpoints for both conditions.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.
Finally, NetScout Systems, Inc. (NASDAQ:NTCT), decreased -1.60%, to $36.31.
Tektronix Communications, a wholly owned partner of NETSCOUT SYSTEMS, INC., will extend the availability, reliability and capability of its TrueCall® geoanalytics platform through signing with Ericsson an Operations Support Systems Interoperability Initiative (OSSii) agreement.
TrueCall is a real-time 24×7 network-wide geoanalytics platform. It hosts a suite of applications that provide monitoring, visualization, optimization, automation, and data monetization solutions. With this OSSii agreement, Tektronix Communications can enhance TrueCall’s reach and availability across a wider set of radio access technology (RAT) types and administration systems.
Richard Kenedi, president of service provider business at NETSCOUT, said: “By joining the OSSii program with Ericsson, Tektronix Communications will continue to expand our lead in the RAN geoanalytics space and enhance the multi-vendor capabilities of our platform. This agreement further underscores the availability and reliability of the high-value, mission-critical, real-time, 24×7 network-wide applications supported via TrueCall.”
NetScout Systems, Inc., together with its auxiliaries, designs, develops, manufactures, markets, licenses, sells, and supports network, application, and service assurance solutions in the United States, Europe, Asia, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
